Literature DB >> 7663574

Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation.

E Zavadova1, L Desser, T Mohr.   

Abstract

Polymorphonuclear neutrophils (PMN) can be primed for enhanced release of reactive oxygen species (ROS) by exposure to cytokines and biological response modifiers. ROS are considered to possess tumoricidal activity. The polyenzyme preparation Wobenzym (WE) contains pancreatin, papain, bromelain trypsin and chymotrypsin and is used in adjuvant tumor therapy. We investigated killing of WE-exposed PMN against tumor cells and analyzed WE influence on ROS production in a chemiluminescence assay in PMN in vitro and in vivo. Depending on dose WE stimulates the cytotoxic capacity of PMN in vitro against tumor cells (50 micrograms/ml:p < 0.01). Exposure of PMN to Wobenzym caused a time-dependent significant (p < 0.02) increase in release of ROS. Similarly, oral administration of Wobenzym to healthy volunteers (n = 28) resulted in significant increases (p < 0.01) in ROS production, depending on dose (peak with 20 tablets) and time (peak 4 hours after Wobenzym administration). In contrast, ROS production was not elevated in the PMN of healthy volunteers receiving placebo (n = 8) or no treatment (n = 16). These findings point to an immunomodulatory capacity of WE in adjuvant tumor therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7663574     DOI: 10.1089/cbr.1995.10.147

Source DB:  PubMed          Journal:  Cancer Biother        ISSN: 1062-8401


  5 in total

Review 1.  Systemic enzyme therapy in oncology: effect and mode of action.

Authors:  J Leipner; R Saller
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  Effect of bromelain on milk yield, milk composition and mammary health in dairy goats.

Authors:  A Contreras; M J Paape; R H Miller; J C Corrales; C Luengo; A Sánchez
Journal:  Trop Anim Health Prod       Date:  2008-07-27       Impact factor: 1.559

3.  Potential role of bromelain in clinical and therapeutic applications.

Authors:  Vidhya Rathnavelu; Noorjahan Banu Alitheen; Subramaniam Sohila; Samikannu Kanagesan; Rajendran Ramesh
Journal:  Biomed Rep       Date:  2016-07-18

4.  Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; David Lawson Morris
Journal:  J Exp Clin Cancer Res       Date:  2014-11-12

Review 5.  Beneficial Properties of Bromelain.

Authors:  Pawel Hikisz; Joanna Bernasinska-Slomczewska
Journal:  Nutrients       Date:  2021-11-29       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.